NEUPHORIA THERAPEUTICS INC
NEUPNASDAQπ #4689 by market capEarnings Feb 15US Equity
$2.35β² $0.03 (+1.29%)
Market closed Β· at closeTrack NEUP
Get earnings, price moves & breaking news on Telegram
24hβ² 1.3%
7dβΌ 5.6%
14dβΌ 16.7%
30dβΌ 33.6%
ytdβΌ 38.5%
1yβΌ 47.0%
π¦Market Cap
$13M
Small Cap
πRevenue Growth (YoY)
β
πGross Margin
β
π΅FCF Margin
β
βοΈP/S Ratio
10.8x
Elevated
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- $2.28 β $2.36
- 52-Week Range
- $2.26 β $5.53
- Volume (shares)
- 55,961
- Avg Volume (shares)
- β
- Shares Outstanding
- 5.4M
- Next Earnings
- 2027-02-15
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- β
- P/E Ratio
- β
- P/S Ratio
- 10.8x
- EPS (TTM)
- $-5.00
- Dividend Yield
- β
- Dilution (1yr)
- +19.3%
NEUPHORIA THERAPEUTICS INC
NEUPFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1MβΌ β92.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
43.5%βΌ β54.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$10Mβ² +768.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$12MβΌ β116.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
5.4Mβ² +19.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$19MβΌ β$3M YoY
About NEUPHORIA THERAPEUTICS INC
Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
βοΈValuationβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst Ratings
βConsensus
Sell
6 analysts
Strong Buy0
Buy0
Hold3
Sell1
Strong Sell2
Ratings as of Nov 2026
Latest News & Updates
News unavailable.